New Veeva Study Builder Agent to Configure Clinical Studies in as Little as One Day Cision · Sep 24, 2026
Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes Cision · Sep 24, 2026
Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development Cision · Sep 23, 2026
Abbott And Berry Street Partner To Expand Personalized Nutrition Support For Consumers Seeking Better Metabolic Health Cision · Sep 23, 2026
Oxford Biomedica Advances Global Quality Transformation with Veeva Quality Cloud Cision · Sep 23, 2026
Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens Cision · Sep 22, 2026
Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding Cision · Sep 22, 2026
Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders Cision · Sep 22, 2026
